Mitochondrial-Derived Peptide

MOTS-c

Exciting mitochondrial peptide with strong preclinical data but limited human trials.

AMPK signalingFolate-methionine cycleAICAR pathwayNRF2 antioxidant response

52 C+

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is an endogenous mitochondrial-derived peptide discovered in 2015. It has shown remarkable metabolic effects in animal models, including improved insulin sensitivity, enhanced exercise capacity, and protection against diet-induced obesity. Human trial data remains extremely limited.

Mechanism of Action

MOTS-c is encoded in the mitochondrial genome and functions as a signaling peptide that translocates to the nucleus under metabolic stress. It activates AMPK via the folate cycle and AICAR accumulation, modulating gene expression related to glucose metabolism, fatty acid oxidation, and antioxidant defense.

Evidence Base

Primarily animal model data (mice). The original discovery paper (Cell Metabolism, 2015) demonstrated metabolic effects. A small human observational study showed that circulating MOTS-c levels correlate with metabolic health. No controlled human interventional trials have been published.

Gene Pathway Detail

MOTS-c activates AMPK signaling, leading to downstream effects on PGC-1α (mitochondrial biogenesis), NRF2 (antioxidant gene expression), and GLUT4 translocation (glucose uptake). It also modulates the folate-methionine cycle, affecting one-carbon metabolism and epigenetic regulation through SAM-dependent methylation.

mRNA Monitoring Insight

While human data is limited, the AMPK and NRF2 gene targets are well-established and monitorable. Biomeme's transcriptomic platform could provide early molecular evidence of MOTS-c pathway engagement in human users, contributing to the evidence base for this emerging peptide.

Safety Considerations

Limited human safety data. Endogenously produced, suggesting a favorable safety profile, but exogenous administration pharmacokinetics are poorly characterized in humans. Not FDA-approved. Available through research chemical and compounding pharmacy channels.

FAQ

Is MOTS-c available for human use?

MOTS-c is not FDA-approved and is primarily available through research chemical suppliers or compounding pharmacies. Human dosing protocols are based on extrapolation from animal data and anecdotal reports, not controlled trials.

Quick Facts

Category: Mitochondrial-Derived Peptide
Score: 52/100 (C+)
Gene Pathways: 4 characterized

Sources

[1] MOTS-c Discovery — Cell Metabolism 2015

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.